JPH08507525A - Hla−a2.1結合ペプチドおよびそれらの使用 - Google Patents
Hla−a2.1結合ペプチドおよびそれらの使用Info
- Publication number
- JPH08507525A JPH08507525A JP6520190A JP52019094A JPH08507525A JP H08507525 A JPH08507525 A JP H08507525A JP 6520190 A JP6520190 A JP 6520190A JP 52019094 A JP52019094 A JP 52019094A JP H08507525 A JPH08507525 A JP H08507525A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- peptides
- residues
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Confectionery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.HLA-A2.1結合モチーフを有する免疫原性ペプチドを含んで成る組成物であ って、前記免疫原性ペプチドが9個の残基及び次の残基: I,V,A及びTから成る群から選択されたN−末端からの位置2での第1の 保存された残基; V,L,I,A及びMから成る群から選択されたC−末端位置での第2の保存 された残基、 を有することを特徴とする組成物。 2.HLA-A2.1結合モチーフを有する免疫原性ペプチドを含んで成る組成物であ って、前記免疫原性ペプチドが9個の残基、すなわち L,M,I,V,A及びTから成る群から選択されたN−末端からの位置2で の第1の保存された残基; A及びMから成る群から選択されたC−末端位置での第2の保存された残基、 を有することを特徴とする組成物。 3.位置1でのアミノ酸がD及びPから成る群から選択されたアミノ酸ではな い請求の範囲第1項記載の組成物。 4.位置1でのアミノ酸がD及びPから成る群から選択されたアミノ酸ではな い請求の範囲第2項記載の組成物。 5.前記N−末端からの位置3でのアミノ酸がD,E,R,K及びHから成る 群から選択されたアミノ酸ではない請求の範囲第1項記載の組成物。 6.前記N−末端からの位置3でのアミノ酸がD,E,R,K及びHから成る 群から選択されたアミノ酸ではない請求の範囲第2項記載の組成物。 7.前記N−末端からの位置6でのアミノ酸がR,K及びHから成る群から選 択されたアミノ酸ではない請求の範囲第1項記載の組成物。 8.前記N−末端からの位置6でのアミノ酸がR,K及びHから成る群から選 択されたアミノ酸ではない請求の範囲第2項記載の組成物。 9.前記N−末端からの位置7でのアミノ酸がR,K,H,D及びEから成る 群から選択されたアミノ酸ではない請求の範囲第1項記載の組成物。 10.前記N−末端からの位置7でのアミノ酸がR,K,H,D及びEから成る 群から選択されたアミノ酸ではない請求の範囲第2項記載の組成物。 11.HLA-A2.1結合モチーフを有する免疫原性ペプチドを含んで成る組成物であ って、前記免疫原性ペプチドが約10個の残基、すなわち L,M,I,V,A及びTから成る群から選択されたN−末端からの位置2で の第1の保存された残基;及び V,I,L,A及びMから成る群から選択されたC−末端位置での第2の保存 された残基を有し、 ここで前記第1及び第2の保存された残基が7個の残基により分けられている ことを特徴とする組成物。 12.位置1でのアミノ酸がD,E及びPから成る群から選択されたアミノ酸で はない請求の範囲第11項記載の組成物。 13.前記N−末端からの位置3でのアミノ酸がD及びEから成る群から選択さ れたアミノ酸ではない請求の範囲第11項記載の組成物。 14.前記N−末端からの位置4でのアミノ酸がA,K,R及びH から成る群から選択されたアミノ酸ではない請求の範囲第11項記載の組成物。 15.前記N−末端からの位置5でのアミノ酸がPではない請求の範囲第11項記 載の組成物。 16.前記N−末端からの位置7でのアミノ酸がR,K及びHから成る群から選 択されたアミノ酸ではない請求の範囲第11項記載の組成物。 17.前記N−末端からの位置8でのアミノ酸がD,E,R,K及びHから成る 群から選択されたアミノ酸ではない請求の範囲第11項記載の組成物。 18.前記N−末端からの位置9でのアミノ酸がR,K及びHから成る群から選 択されたアミノ酸ではない請求の範囲第11項記載の組成物。 19.医薬的に許容できるキャリヤー、及びHLA-A2.1分子を結合することができ 且つ哺乳類において免疫応答を誘発することができるペプチドの治療的有効量を 含んで成る医薬組成物。 20.前記ペプチドがTLGIVCPIのような式を有する請求の範囲第19項記載の医薬 組成物。 21.YMLDLQPETTのような式を有するペプチドをさらに含んで成る請求の範囲第 19項記載の医薬組成物。 22.Tヘルパーペプチドをさらに含んで成る請求の範囲第19項記載の医薬組成 物。 23.前記TヘルパーペプチドがaKXVAAWTLKAAa〔ここで、aはD−アラニンで あり、そしてXはシクロヘキシルアラニンである〕のような式を有する請求の範 囲第22項記載の医薬組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2714693A | 1993-03-05 | 1993-03-05 | |
US08/027,146 | 1993-03-05 | ||
US7320593A | 1993-06-04 | 1993-06-04 | |
US08/073,205 | 1993-06-04 | ||
US15918493A | 1993-11-29 | 1993-11-29 | |
US08/159,184 | 1993-11-29 | ||
PCT/US1994/002353 WO1994020127A1 (en) | 1993-03-05 | 1994-03-04 | Hla-a2.1 binding peptides and their uses |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08507525A true JPH08507525A (ja) | 1996-08-13 |
JP3908271B2 JP3908271B2 (ja) | 2007-04-25 |
Family
ID=27362951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52019094A Expired - Fee Related JP3908271B2 (ja) | 1993-03-05 | 1994-03-04 | Hla−a2.1結合ペプチドおよびそれらの使用 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0703783B1 (ja) |
JP (1) | JP3908271B2 (ja) |
KR (1) | KR960700739A (ja) |
CN (1) | CN1118572A (ja) |
AT (1) | ATE466869T1 (ja) |
AU (2) | AU6359494A (ja) |
BR (1) | BR9406652A (ja) |
CA (1) | CA2157510A1 (ja) |
DE (1) | DE69435292D1 (ja) |
NZ (1) | NZ263050A (ja) |
SG (1) | SG49008A1 (ja) |
WO (1) | WO1994020127A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002518346A (ja) * | 1998-06-17 | 2002-06-25 | エピミューン, インコーポレイテッド | Hla結合ペプチドおよびそれらの用途 |
JP2003535024A (ja) * | 1999-06-29 | 2003-11-25 | エピミューン インコーポレイテッド | Hla結合ペプチドおよびそれらの使用 |
WO2005007694A1 (ja) * | 2003-07-16 | 2005-01-27 | Green Peptide Co., Ltd. | HER2/neuペプチドおよびその治療上の用途 |
WO2005028503A1 (ja) * | 2003-09-22 | 2005-03-31 | Green Peptide Co., Ltd. | C型肝炎ウイルス由来ペプチド |
JP2008505636A (ja) * | 2004-07-03 | 2008-02-28 | モガム バイオテクノロジー リサーチ インスティチュート | Hcvに有効なctl反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途 |
JPWO2005105993A1 (ja) * | 2004-04-30 | 2008-03-13 | 日本電気株式会社 | Hla結合性ペプチド、その前駆体、それをコードするdna断片および組み換えベクター |
JP2012516140A (ja) * | 2009-01-28 | 2012-07-19 | エピミューン,インコーポレイティド | Pan−dr結合ポリペプチドおよびその使用 |
JP2012229225A (ja) * | 2006-02-07 | 2012-11-22 | Nec Corp | Hla結合性ペプチド、それをコードするdna断片および組み換えベクター |
US8324345B2 (en) | 2006-10-12 | 2012-12-04 | Nec Corporation | HLA-binding peptide, precursor thereof, DNA fragment and recombinant vector encoding the same |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674978A (en) * | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
US6607727B1 (en) | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
US5780036A (en) * | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
US6689363B1 (en) | 1992-01-29 | 2004-02-10 | Epimmune Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
US7611713B2 (en) | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
US20020168374A1 (en) * | 1992-08-07 | 2002-11-14 | Ralph T. Kubo | Hla binding peptides and their uses |
US6235288B1 (en) | 1992-08-26 | 2001-05-22 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
US5651993A (en) | 1992-11-18 | 1997-07-29 | Yale University | Specific immune system modulation |
US6328971B1 (en) * | 1993-01-22 | 2001-12-11 | Ludwig Institute For Cancer Research | MAGE-1 derived nona peptides, and compositions thereof |
CN1118573A (zh) * | 1993-02-26 | 1996-03-13 | 斯克瑞普斯研究所 | 诱导细胞毒t淋巴细胞应答乙型肝炎病毒的肽类 |
US9266930B1 (en) | 1993-03-05 | 2016-02-23 | Epimmune Inc. | Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
ES2187530T3 (es) * | 1993-08-02 | 2003-06-16 | Scripps Research Inst | Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b. |
NZ271774A (en) * | 1993-08-06 | 1998-02-26 | Cytel Corp | Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen |
PT735893E (pt) | 1993-09-14 | 2009-03-06 | Pharmexa Inc | Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária |
US6413935B1 (en) | 1993-09-14 | 2002-07-02 | Epimmune Inc. | Induction of immune response against desired determinants |
CN1055701C (zh) * | 1993-10-19 | 2000-08-23 | 味之素株式会社 | 能诱导对hiv免疫应答的肽及含有该肽的预防、治疗aids的药物 |
US5550214A (en) * | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
US5709995A (en) * | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
US5554724A (en) * | 1994-03-24 | 1996-09-10 | University Of Leiden | Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof |
US5585461A (en) * | 1994-03-24 | 1996-12-17 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US5851523A (en) * | 1994-03-24 | 1998-12-22 | Ludwig Institute For Cancer Research. | Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof |
US5554506A (en) * | 1994-03-24 | 1996-09-10 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US5686068A (en) * | 1994-03-24 | 1997-11-11 | Ludwig Institute For Cancer Research | Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof |
DE69517521T2 (de) * | 1994-04-08 | 2001-03-08 | Us Gov Health & Human Serv | Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes |
US5935797A (en) * | 1994-06-16 | 1999-08-10 | Stanford University | Interaction of MHC Class II proteins with members of the PCNA family of proteins |
SE9403526D0 (sv) | 1994-10-14 | 1994-10-14 | Astra Ab | New Peptides |
CA2207736A1 (en) | 1994-12-14 | 1996-06-20 | The Scripps Research Institute | In vivo activation of tumor-specific cytotoxic t cells |
CA2210812C (en) * | 1995-01-16 | 2009-09-01 | Nicholas Manolios | T-cell affecting peptides |
GB9501300D0 (en) * | 1995-01-24 | 1995-03-15 | Boughton Brian J | Peptides which inhibit viruses |
US5874531A (en) * | 1995-03-07 | 1999-02-23 | President And Fellows Of Harvard College | Identification of self and non-self antigens implicated autoimmune disease |
US6514942B1 (en) * | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
SE9501067D0 (sv) | 1995-03-24 | 1995-03-24 | Astra Ab | New peptides |
US6156316A (en) * | 1995-05-08 | 2000-12-05 | Sloan-Kettering Institute For Cancer Research | Oncogene fusion protein peptide vaccines |
US5698396A (en) * | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
US6140464A (en) * | 1995-06-07 | 2000-10-31 | Ludwig Institute For Cancer Research | Nonapeptides that bind a HLA-A2.1 molecule |
US5858972A (en) * | 1996-01-11 | 1999-01-12 | La Jolla Cancer Research Foundation | Antithrombotic agents and methods of use |
CA2242878C (en) * | 1996-01-24 | 2010-06-22 | Cytel Corporation | Induction of immune response against desired determinants |
US5723579A (en) * | 1996-02-02 | 1998-03-03 | Bayer Corporation | Fibrinogen binding peptides |
US6143509A (en) * | 1996-02-06 | 2000-11-07 | Abbott Laboratories | Prostate specific antigen peptides and uses thereof |
US7001600B1 (en) | 1996-02-09 | 2006-02-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes |
US6946133B1 (en) | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
EP1767542B1 (en) * | 1996-03-21 | 2016-05-11 | Epimmune Inc. | HLA-A2.1 binding peptides and their uses |
WO1997034621A1 (en) * | 1996-03-21 | 1997-09-25 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
ATE408617T1 (de) | 1996-06-11 | 2008-10-15 | Northern Sydney And Central Co | T zell antigen rezeptor peptide |
US6465251B1 (en) | 1996-11-13 | 2002-10-15 | Dana-Farber Cancer Institute, Inc. | Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin |
US6287756B1 (en) * | 1997-05-05 | 2001-09-11 | Ludwig Institute For Cancer Research | Methods for determining presence of cancer in a sample by determining expression of an SSX gene |
AU753780B2 (en) * | 1997-08-01 | 2002-10-31 | Bio-Rad Laboratories, Inc. | Synthetic antigen for the detection of antibodies immunoreactive with HIV virus |
US6291430B1 (en) | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
US6716809B1 (en) | 1997-09-12 | 2004-04-06 | Ludwig Institute For Cancer Research | Mage-A3 peptides presented by HLA class molecules |
US6183746B1 (en) | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
US6013258A (en) * | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
EP1049711B1 (en) * | 1998-01-19 | 2003-12-10 | Mogam Biotechnology Research Institute | Liposomes comprising peptide antigens derived from x protein of hepatitis b virus |
WO1999040930A1 (en) | 1998-02-12 | 1999-08-19 | Center For Blood Research, Inc. | Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases |
US20040002117A1 (en) | 1998-02-12 | 2004-01-01 | Hogan Patrick G. | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases |
US6734287B1 (en) | 1998-04-09 | 2004-05-11 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
EP0955311A3 (en) * | 1998-04-09 | 2000-08-16 | Idexx Laboratories, Inc. | Peptide vaccine for canine allergy |
IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
CA2341642C (en) * | 1998-09-01 | 2011-05-24 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor |
GB9826143D0 (en) * | 1998-11-27 | 1999-01-20 | Ludwig Inst Cancer Res | Tumour rejection antigens |
IT1309584B1 (it) * | 1999-02-26 | 2002-01-24 | San Raffaele Centro Fond | Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso. |
AU757334B2 (en) * | 1999-03-30 | 2003-02-13 | Idexx Laboratories, Inc. | Specific binding proteins for treating canine allergy |
WO2000058349A1 (en) * | 1999-03-30 | 2000-10-05 | Idexx Laboratories, Inc. | Peptide vaccine for canine allergy |
EP1176986B1 (en) | 1999-04-20 | 2018-07-04 | Yale University | Differentiation of monocytes into functional dendritic cells |
US7129052B1 (en) | 2000-07-12 | 2006-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins |
JP4873810B2 (ja) * | 1999-10-05 | 2012-02-08 | エピミューン インコーポレイテッド | ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−1に対する細胞性免疫応答の誘導 |
ATE445643T1 (de) | 1999-11-18 | 2009-10-15 | Pharmexa Inc | Heteroklitische analoga von klasse-i epitopen |
CA2396739A1 (en) * | 1999-12-06 | 2001-06-14 | Krishna G. Peri | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
US6602510B1 (en) | 2000-04-05 | 2003-08-05 | Epimmune Inc. | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
AU2273701A (en) * | 1999-12-13 | 2001-06-18 | Epimmune, Inc. | Hla class i a2 tumor associated antigen peptides and vaccine compositions |
US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
CA2400215A1 (en) * | 2000-02-23 | 2001-08-30 | Epimmune Inc. | Hla binding peptides and their uses |
CA2413211A1 (en) | 2000-04-04 | 2001-10-11 | University Of Rochester | A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
IL152655A0 (en) * | 2000-05-12 | 2003-06-24 | Northwest Biotherapeutics Inc | Method to increase class i presentation of exogenous antigens by human dendritic cells |
FR2809402A1 (fr) * | 2000-05-26 | 2001-11-30 | Dev Des Antigenes Combinatoire | Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c |
FR2812087B1 (fr) * | 2000-07-21 | 2007-05-11 | Inst Nat Sante Rech Med | Procede de criblage de peptides utilisables en immunotherapie |
WO2002018578A2 (en) | 2000-08-28 | 2002-03-07 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer |
WO2002020616A1 (en) * | 2000-09-01 | 2002-03-14 | Epimmune Inc. | Hla-a2.1 binding peptides and their uses |
EP1195381A1 (de) * | 2000-09-28 | 2002-04-10 | Immusystems GmbH | CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope |
ATE536187T1 (de) | 2000-10-19 | 2011-12-15 | Epimmune Inc | Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen |
US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
WO2002077012A2 (en) | 2001-03-23 | 2002-10-03 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Human papilloma virus immunoreative peptides |
US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
CA2443123A1 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
EP1425408A4 (en) | 2001-08-17 | 2004-11-10 | Neose Technologies Inc | CHEMICAL-ENZYMATIC SYNTHESIS OF SIALYL OLIGOSACCHARIDES |
WO2003022995A2 (en) | 2001-09-06 | 2003-03-20 | Agensys, Inc. | Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer |
IL145926A0 (en) | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
FR2839722A1 (fr) | 2002-05-17 | 2003-11-21 | Bio Merieux | Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c |
AU2003274463B2 (en) | 2002-06-10 | 2009-10-29 | University Of Rochester | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
CA2484941A1 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
CN1691964A (zh) * | 2002-09-06 | 2005-11-02 | 曼康公司 | 表位序列 |
EP2402026A3 (en) | 2002-09-13 | 2012-04-18 | Intercell AG | Method for isolating hepatitis C virus peptides |
CA2500715A1 (en) | 2002-10-03 | 2004-04-15 | Epimmune, Inc. | Hla binding peptides and their uses |
EP1903056A3 (en) | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof |
AU2003293807A1 (en) * | 2002-12-24 | 2004-07-22 | Algonomics N.V. | Mhc class i restricted t-cell stimulating peptides from hepatitis b virus |
EP1594892A2 (en) | 2003-02-10 | 2005-11-16 | Agensys, Inc. | Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
WO2004073625A2 (en) | 2003-02-14 | 2004-09-02 | Provid Pharmaceuticals, Inc. | Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof |
ES2562456T3 (es) | 2003-03-24 | 2016-03-04 | Valneva Austria Gmbh | Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes |
WO2004092207A2 (en) * | 2003-04-16 | 2004-10-28 | Algonomics N.V. | Respiratory syncytial virus (rsv) peptides |
EP1620456B1 (en) | 2003-04-18 | 2014-02-26 | Biotech Synergy, Inc. | Hla-a2 tumor associated antigen peptides and compositions |
PL1629088T3 (pl) | 2003-05-30 | 2012-06-29 | Agensys Inc | Warianty antygenu komórek macierzystych stercza (PSCA) i ich podsekwencje |
EP1648502B1 (en) | 2003-07-11 | 2010-12-01 | Intercell AG | Hcv vaccines |
US7348007B2 (en) * | 2004-02-09 | 2008-03-25 | Ludwig Institute For Cancer Research | Mage C2 antigenic peptides and uses thereof |
CA2567449C (en) | 2004-05-28 | 2014-03-11 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
US7785875B2 (en) | 2004-07-03 | 2010-08-31 | Mogam Biotechnology Research Institute | Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same |
ITRM20050297A1 (it) * | 2005-06-08 | 2006-12-09 | Univ Siena | Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi. |
FR2887884B1 (fr) * | 2005-06-29 | 2007-09-14 | Pasteur Institut | Epitopes de la proteine hbsp et leurs applications biotechnologiques et medicales, notamment pour le traitement de l'hepatite b chronique |
US8945573B2 (en) | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
CA2812110A1 (en) * | 2005-09-08 | 2007-03-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
EP3085707B1 (en) | 2007-11-01 | 2019-02-27 | Mayo Foundation for Medical Education and Research | Hla-dr binding peptides and their uses |
DE102007059924A1 (de) * | 2007-12-03 | 2009-06-04 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Allel- und Isotyp-spezifische Intervention an mit Autoimmunerkrankungen assoziierten MHC-Klasse-II-Molekülen durch Peptide |
US8367801B2 (en) * | 2008-01-10 | 2013-02-05 | Endocrine Pharmaceuticals Limited | Proteinaceous compounds |
US8986712B2 (en) * | 2009-11-29 | 2015-03-24 | Yeda Research And Development Co., Ltd. | Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation |
GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
WO2018005559A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
CN111093691A (zh) | 2017-04-03 | 2020-05-01 | 内恩疗法公司 | 蛋白质抗原及其用途 |
CA3081840A1 (en) | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
FR3087448B1 (fr) | 2018-10-23 | 2023-10-13 | Pdc Line Pharma | Lignee pdc modifiee pour secreter une cytokine |
US20210380644A1 (en) * | 2018-10-26 | 2021-12-09 | Saint Louis University | Peptides for inducing heterosubtypic influenza t cell responses |
JP2022536695A (ja) | 2019-06-12 | 2022-08-18 | ビオンテック ユーエス インコーポレイテッド | 新抗原組成物およびその使用 |
WO2022036137A1 (en) | 2020-08-13 | 2022-02-17 | Biontech Us Inc. | T cell manufacturing compositions and methods |
MX2023001851A (es) | 2020-08-13 | 2023-04-26 | Biontech Us Inc | Neoantigenos ras y usos de los mismos. |
JP2024501482A (ja) | 2020-12-14 | 2024-01-12 | ビオンテック ユーエス インコーポレイテッド | がん免疫療法のための組織特異的抗原 |
AU2022350653A1 (en) | 2021-09-22 | 2024-05-02 | BioNTech SE | Coronavirus vaccines and methods of use |
WO2023064612A2 (en) | 2021-10-15 | 2023-04-20 | BioNTech SE | Pharmaceutical compositions for delivery of viral antigens and related methods |
WO2023147090A1 (en) | 2022-01-27 | 2023-08-03 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105554A (en) * | 1992-05-05 | 1999-08-17 | Univ Leiden | Peptides of human papillomavirus for use in preparations elicit a human T cell response |
ATE183514T1 (de) * | 1992-05-26 | 1999-09-15 | Univ Leiden | Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten |
NZ255683A (en) * | 1992-08-07 | 1996-08-27 | Cytel Corp | Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif |
DE4238416A1 (de) * | 1992-11-13 | 1994-05-19 | Max Planck Gesellschaft | Bestimmung von Peptidmotiven auf MHC-Molekülen |
IL109664A0 (en) * | 1993-05-18 | 1994-08-26 | Rijksuniversiteit | Peptides of human influenza virus for use in human t cell response inducing compositions |
US6660276B1 (en) * | 1994-02-16 | 2003-12-09 | The University Of Virginia Patent Foundation | Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor |
-
1994
- 1994-03-04 EP EP94910837A patent/EP0703783B1/en not_active Expired - Lifetime
- 1994-03-04 AT AT94910837T patent/ATE466869T1/de not_active IP Right Cessation
- 1994-03-04 WO PCT/US1994/002353 patent/WO1994020127A1/en active Application Filing
- 1994-03-04 DE DE69435292T patent/DE69435292D1/de not_active Expired - Lifetime
- 1994-03-04 NZ NZ263050A patent/NZ263050A/en unknown
- 1994-03-04 BR BR9406652A patent/BR9406652A/pt not_active Application Discontinuation
- 1994-03-04 CA CA002157510A patent/CA2157510A1/en not_active Abandoned
- 1994-03-04 CN CN94191364A patent/CN1118572A/zh active Pending
- 1994-03-04 KR KR1019950703753A patent/KR960700739A/ko not_active Application Discontinuation
- 1994-03-04 AU AU63594/94A patent/AU6359494A/en not_active Abandoned
- 1994-03-04 SG SG1996005140A patent/SG49008A1/en unknown
- 1994-03-04 JP JP52019094A patent/JP3908271B2/ja not_active Expired - Fee Related
-
1998
- 1998-05-18 AU AU65979/98A patent/AU6597998A/en not_active Abandoned
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002518346A (ja) * | 1998-06-17 | 2002-06-25 | エピミューン, インコーポレイテッド | Hla結合ペプチドおよびそれらの用途 |
JP2003535024A (ja) * | 1999-06-29 | 2003-11-25 | エピミューン インコーポレイテッド | Hla結合ペプチドおよびそれらの使用 |
WO2005007694A1 (ja) * | 2003-07-16 | 2005-01-27 | Green Peptide Co., Ltd. | HER2/neuペプチドおよびその治療上の用途 |
WO2005028503A1 (ja) * | 2003-09-22 | 2005-03-31 | Green Peptide Co., Ltd. | C型肝炎ウイルス由来ペプチド |
EA009782B1 (ru) * | 2003-09-22 | 2008-04-28 | Грин Пептайд Ко., Лтд. | Пептид, происходящий из вируса гепатита с |
JPWO2005105993A1 (ja) * | 2004-04-30 | 2008-03-13 | 日本電気株式会社 | Hla結合性ペプチド、その前駆体、それをコードするdna断片および組み換えベクター |
JP2011120598A (ja) * | 2004-04-30 | 2011-06-23 | Nec Corp | Hla結合性ペプチド、それをコードするdna断片および組み換えベクター |
JP2008505636A (ja) * | 2004-07-03 | 2008-02-28 | モガム バイオテクノロジー リサーチ インスティチュート | Hcvに有効なctl反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途 |
JP2012229225A (ja) * | 2006-02-07 | 2012-11-22 | Nec Corp | Hla結合性ペプチド、それをコードするdna断片および組み換えベクター |
US9045531B2 (en) | 2006-02-07 | 2015-06-02 | Nec Corporation | HLA-binding peptide, precursor thereof, and DNA fragment and recombinant vector coding for said HLA-binding peptide |
US8324345B2 (en) | 2006-10-12 | 2012-12-04 | Nec Corporation | HLA-binding peptide, precursor thereof, DNA fragment and recombinant vector encoding the same |
JP2012516140A (ja) * | 2009-01-28 | 2012-07-19 | エピミューン,インコーポレイティド | Pan−dr結合ポリペプチドおよびその使用 |
Also Published As
Publication number | Publication date |
---|---|
CA2157510A1 (en) | 1994-09-15 |
AU6359494A (en) | 1994-09-26 |
EP0703783A4 (en) | 1999-03-10 |
WO1994020127A1 (en) | 1994-09-15 |
EP0703783B1 (en) | 2010-05-05 |
BR9406652A (pt) | 1996-09-10 |
SG49008A1 (en) | 1998-05-18 |
KR960700739A (ko) | 1996-02-24 |
CN1118572A (zh) | 1996-03-13 |
JP3908271B2 (ja) | 2007-04-25 |
AU6597998A (en) | 1998-07-02 |
DE69435292D1 (de) | 2010-06-17 |
EP0703783A1 (en) | 1996-04-03 |
WO1994020127A9 (en) | 2003-04-17 |
ATE466869T1 (de) | 2010-05-15 |
NZ263050A (en) | 1997-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3908271B2 (ja) | Hla−a2.1結合ペプチドおよびそれらの使用 | |
EP1917970B1 (en) | Hla binding peptides and their uses | |
EP1911461B1 (en) | HLA class I and II binding peptides and their uses | |
AU725550B2 (en) | HLA binding peptides and their uses | |
US7252829B1 (en) | HLA binding peptides and their uses | |
US20070055049A1 (en) | HLA binding motifs and peptides and their uses | |
JP2003509465A (ja) | ペプチドおよび核酸組成物を使用する、c型肝炎ウイルスに対する細胞性免疫応答の誘導 | |
JP2002515869A (ja) | Hla―a2.1結合ペプチド及びその使用 | |
US20100068228A1 (en) | Inducing Cellular Immune Responses to Hepatitis B Virus Using Peptide and Nucleic Acid Compositions | |
JP2010090167A (ja) | Hla結合ペプチドおよびそれらの用途 | |
JP2003524016A (ja) | Hla結合ペプチドおよびそれらの用途 | |
US20030185822A1 (en) | HLA-A2.1 binding peptides and their uses | |
JP2004517609A (ja) | Hla−a2.1結合ペプチドおよびそれらの用途 | |
US20040157780A1 (en) | CTL inducing peptides from c-erb2 (HER-2/neu) | |
CA2421448A1 (en) | Hla binding peptides and their uses | |
KR20030036139A (ko) | Hla 결합 펩티드 및 이의 용도 | |
MXPA98007706A (en) | Peptides of union to locus a of human leukocytes and its u |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041227 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060824 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061219 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070118 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100126 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100126 Year of fee payment: 3 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100126 Year of fee payment: 3 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100126 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100126 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100126 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110126 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120126 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130126 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |